Article
A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C.
Hepatology (Baltimore, Md.) - 1 Apr 2001
Mangia A, Minerva N, Annese M, Leandro G, Villani M R, Santoro R, Carretta V, Bacca D, Giangaspero A, Bisceglia M, Ventrella F, Dell'Erba G, Andriulli A
Abstract excerpt
The aim of this study was to compare, in an open-label study, the efficacy and safety of a combination of interferon (IFN) and amantadine (AMA) with that of IFN alone in previously untreated patients with chronic hepatitis C. A total of 200 patients were randomized to 6 MU of IFN-alpha2a 3 times per week, with 200 mg of AMA daily (n = 99) or to an identical dose of interferon alpha2a (n = 101). Patients were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.